M. Graf

Most-cited papers

1. A HIF-regulated VHL-PTP1B-Src signaling axis identifies a therapeutic target in Renal Cell Carcinoma

   N. Suwaki, Elsa Vanhecke, K. Atkins, M. Graf +21 more

   2011Science Translational Medicine66 citations Open access

   Semantic Scholar

   Save

2. Impact of mutational profiles on response of primary oestrogen receptor-positive breast cancers to oestrogen deprivation

   Pascal Gellert, Corrinne V. Segal, Qiong Gao, E. López-Knowles +22 more

   2016Nature Communications36 citations Open access

   Semantic Scholar

   Save

3. Abstract P2-05-01: Clinico-pathological relationships with Ki67 in POETIC (CRUK/07/015) – Critical lessons for assessing Ki67 for prognosis and as a pharmacodynamic marker

   J. Bliss, J. Morden, Andrew Evans, C. Holcombe +14 more

   20176 citations

   Semantic Scholar

   Save

4. Dose intensity phase III trial with ifosfamide, carboplatin, etoposide, and vincristine combined with filgastrim (CEV-Ifo + G) in patients with small-cell lung cancer (SCLC)

   A. Hanauske, A. Korfel, M. Perker, B. Heinrich +8 more

   19980 citations

   Semantic Scholar

   Save

5. Neoadjuvant chemotherapy (EAP) with r-melHuG-CSF (Filgrastim) for patients with locally advanced gastric cancer

   U. Fink, C. Schuhmacher, K. Böttcher, G. Schwob +3 more

   19930 citations

   Semantic Scholar

   Save